Zydus Lifesciences taps US markets with the launch of Lenalidomide Capsules

20 Sep 2022 , 03:06 PM

Zydus Lifesciences Limited (previously Cadila Healthcare Limited) announced the launch of Lenalidomide Capsules in the United States. Previously, the company got final clearances for 5 mg, 10 mg, 15 mg, and 25 mg dosages, as well as preliminary approvals for 2.5 mg and 20 mg strengths.

Lenalidomide is a cancer treatment medication that works in slowing or preventing cancer cell proliferation. It is also used to treat anaemia in those with blood/bone marrow abnormalities (myelodysplastic syndromes-MDS). The medication is produced in the group’s formulation manufacturing plant in Ahmedabad SEZ, India.

According to IQVIA MAT July 2022, lenalidomide had yearly sales of $2.86 billion in the United States markets.

At around 3.08 PM, Zydus Lifesciences was trading at Rs370.80 up by 3.09% from its previous closing of Rs359.70 on the BSE. The scrip touched intraday high and low of Rs371.25 and Rs359.35 respectively.

For feedback and suggestions, write to us at [e-mail]